Reversing HIV damage `possible'

Aldhous, Peter
March 1995
New Scientist;3/11/95, Vol. 145 Issue 1968, p9
Reports on the possibility of reversing the damage of HIV to the immune system by using interleukin-2. Results of the research conducted by scientists at the National Institutes of Health in Bethesda, Maryland concerning the reversal of the decline in CD4 cells caused by HIV.


Related Articles

  • Interleukin-2 injections produce sustained increases in CD4+ T cell counts in early-stage HIV...  // AIDS Patient Care & STDs;Oct96, Vol. 10 Issue 5, p312 

    States advantages of self-administered injections of interleukin-2 in increasing the mean CD4 T counts in the research in early HIV infection at National Institute of Allergy and Infectious Diseases. Studies in combination with antiretroviral drugs; Toxicities from mild to moderate flu-like...

  • Encouraging data on quality of life reported for IL-2 therapy.  // AIDS Patient Care & STDs;Oct96, Vol. 10 Issue 5, p314 

    Reports findings of a study on the quality of life of HIV-infected patients receiving intravenous interleukin-2 (IL-2) as opposed to oral intake of IL-2. Absence of overall difference in quality of life or symptom distress in both groups; Mild to moderate flu-like symptoms.

  • Interleukin-2 therapy in HIV infection. Pahwa, Savita; Morales, Maripaz // AIDS Patient Care & STDs;Mar1998, Vol. 12 Issue 3, p187 

    Examines the use of interleukin-2 (IL-2) therapy in patients infected with human immunodeficiency virus (HIV). Identification of the role of cytokines in the immune system; Use of interleukin in cancer therapy; Description of mechanisms of IL-2.

  • VIRAL REBOUND DESPITE HAART AND IL-2.  // AIDS Patient Care & STDs;Feb2000, Vol. 14 Issue 2, p101 

    Presents research findings showing that two patients treated with highly active antiretoviral therapy (HAART) regimens and interleukin-2 (IL-2) and who had undetectable viral loads, had quick viral rebound soon after stopping therapy. Support of earlier reports that eradicating HIV from the...

  • Benefit of IL-2 Therapy in HIV Patients Confirmed. Abrams, Donald; Chatfield, Joanne E. // American Family Physician;6/15/2001, Vol. 63 Issue 12, p2424 

    Reports on the confirmation that recombinant interleukin-2 produces a sustained increase in the CD4+ T-cell level for up to one year in some patients with human immunodeficiency virus infection who are receiving antiretroviral drug therapy. Demonstration that the addition of recombinant...

  • IL-2 in HIV Infection: Raises CD4+ Cells, But at What Cost? Winslow, Dean L. // AIDS Alert;Jul2007, Vol. 22 Issue 7, p82 

    Actg 328 was a multicenter trial that studied HIV-1 infected adults without active AIDS-defining illnesses and with CD4+ lymphocyte counts between 50 and 350/uL. Patients were protease inhibitor (PI) and IL-2 naive but may have received prior nucleoside analogue therapy. Patients were treated...

  • Up with T cells.  // Advocate;4/4/95, Issue 678, p12 

    Cites research findings on the use of off-and-on infusions of the natural protein interleukin 2 (IL-2) to boost the immune systems of people with HIV. Side effects of the treatment.

  • Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Chun, Tae-Wook; Engel, Delphine; Mizell, Stephanie B.; Hallahan, Claire W.; Fischette, Maria; Park, Sohee; Davey, Richard T.; Dybul, Mark; Kovacs, Joseph A.; Metcalf, Julia A.; Mican, JoAnn M.; Berrey, M. Michelle; Corey, Lawrence; Lane, H. Clifford; Fauci, Anthony S. // Nature Medicine;Jun1999, Vol. 5 Issue 6, p651 

    The size of the pool of resting CD4[sup +] T cells containing replication-competent HIV in the blood of patients receiving intermittent interleukin (IL)-2 plus highly active anti-retroviral therapy (HAAET) was significantly lower than that of patients receiving HAAET alone. Virus could not be...

  • Latent reservoirs of HIV infection: Flushing with IL-2? Cooper, David A.; Emery, Sean // Nature Medicine;Jun1999, Vol. 5 Issue 6, p611 

    A new study suggests it may be possible to further dilute quantities of infectious HIV in infected people by combining potent anti-retroviral therapy with immune therapy using interleukin-2 (pages 651?655).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics